Advanced Microscopical Non-Invasive Examination of the Supposed Migrastatics for Impact on In Vitro Cell Migration

Loading...
Thumbnail Image
Date
2022-07-02
ORCID
Advisor
Referee
Mark
Journal Title
Journal ISSN
Volume Title
Publisher
European Conference of Oncology Pharmacy
Abstract
Live H1299 lung carcinoma cells in vitro were exposed to selected drugs with a presumed antimigration activity that implies antimetastatic potential and time-lapse examined with Coherence Controlled Holography Microscopy (CCHM) with holographic incoherent light Quantitive Phase Imaging (hiQPI). It is a methodology that online evaluates the dynamics of morphology, migration, and the growth of tumor cells by weighing them. Material and method: Q-Phase (Telight, Brno, Czech Republic) as a commercially available CCHM was employed for the hiQPI of cells. Four putative migrastatics, vincristine (VIN, 100 nM), doxycycline (DOXY, 1 mg/ml), and 4-hydroxyacetophenone (4HAP, 4 M) were tested with H1299, using Ibidi -Slide VI 0.4 for 20 hours recording with Q-Phase. Cells were cultivated at 37°C in a humidified incubator with 3.5% CO2 in standard Eagle MEM medium with 10% fetal bovine serum, 20 M gentamicin, and 2mM L-glutamine. For the time-lapse recording, the medium was enriched with 20 mM HEPES to maintain pH 7.4. Results and discussion: This research showed that on the cancer cell line H1299 the vincristine and doxycycline had the greatest migrastatic effect in the 2D environment under given conditions. These putative migrastatics showed an effect on the dynamics of migration and cell morphology. Conclusion: The hiQPI screening is a reliable and economical approach to in vitro introductory testing of potential migrastatics. hiQPI combines high-precision cell imaging, which is important for cell segmentation and thus tracking cell trajectories, with cell growth measurements, thus providing a comprehensive assessment of a potential risk of some cytopathic issues.
Description
Document type
Document version
Published version
Date of access to the full text
Language of document
en
Study field
Comittee
Date of acceptance
Defence
Result of defence
Document licence
(C) European Conference of Oncology Pharmacy
DOI
Citace PRO